← Esperion Therapeutics, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net loss | ($75.0m) | ($167.0m) | ($201.8m) | ($97.2m) | ($143.6m) | ($269.1m) | ($233.7m) | ($209.2m) | ($51.7m) | ($22.7m) | — | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($75.0m) | ($167.0m) | ($201.8m) | ($97.2m) | ($143.6m) | ($269.1m) | ($233.7m) | ($209.2m) | ($51.7m) | ($22.7m) | — | |
| Depreciation | $252k | $258k | $265k | $319k | $547k | $612k | $500k | $164k | $63k | $105k | $106k | |
| Amortization of Debt Issuance Costs | $23k | $12k | $0 | $0 | $1.7m | $1.6m | $1.6m | $1.7m | $1.5m | $3.0m | — | |
| Accretion and amortization of premiums and discounts on investments | $1.0m | $334k | ($217k) | ($200k) | ($97k) | $12k | $279k | ($412k) | $0 | $0 | — | |
| Deferred Income Tax Expense (Benefit) | — | — | — | — | — | — | — | — | — | $0 | — | |
| Share-based Payment Arrangement, Noncash Expense | $16.0m | $18.6m | $24.0m | $25.9m | $28.4m | $24.3m | $15.2m | $12.0m | $12.0m | $9.9m | $9.9m | |
| Share-based Payment Arrangement, Expense | $15.6m | $18.2m | — | — | — | — | — | — | $12.0m | $9.9m | $9.9m | |
| Stock-based compensation expense | $16.0m | $18.6m | $24.0m | $25.9m | $28.4m | $24.3m | $15.2m | $12.0m | $12.0m | $9.9m | $9.9m | |
| Other Nonoperating Income (Expense) | $1.5m | $2.2m | $2.8m | $4.1m | $515k | $4.0m | $2.7m | $5.3m | $8.0m | $3.5m | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | — | — | — | — | — | $10.5m | $10.8m | $14.8m | $31.6m | $60.0m | ($51.1m) | |
| Accounts receivable | — | — | — | $0 | ($12.4m) | ($10.5m) | ($10.8m) | ($14.8m) | ($31.6m) | ($60.0m) | ($51.1m) | |
| Increase (Decrease) in Inventories | — | — | — | — | $16.1m | $18.3m | $807k | $30.4m | $28.9m | $10.6m | ($4.9m) | |
| Inventories | — | — | $0 | $0 | ($16.1m) | ($18.3m) | ($807k) | ($30.4m) | ($28.9m) | ($10.6m) | ($4.9m) | |
| Increase (Decrease) in Accounts Payable | $3.9m | $15.8m | $24.4m | ($16.1m) | $23.1m | ($34.1m) | $5.6m | $8.7m | $12.4m | $20.9m | ($3.6m) | |
| Deferred revenue | — | — | $0 | $2.2m | ($490k) | $4.7m | ($2.8m) | $21.9m | ($16.9m) | $26.0m | — | |
| Other accrued liabilities | $6.0m | $2.4m | $7.6m | $10.0m | $2.8m | $6.9m | $4.0m | $22.1m | $18.3m | $31.2m | — | |
| Prepaids and other assets | $139k | ($1.7m) | ($2.9m) | ($3.4m) | ($14.8m) | $99k | $1.4m | $6.2m | ($13.9m) | ($30.8m) | — | |
| Net Cash Provided by (Used in) Operating Activities | ($47.7m) |
($131.3m)
-175.09%
|
($148.6m)
-13.20%
|
($70.3m)
+52.68%
|
($85.2m)
-21.09%
|
($263.8m)
-209.72%
|
($174.8m)
+33.73%
|
($135.5m)
+22.50%
|
($23.7m)
+82.54%
|
($13.1m)
+44.65%
|
($18.2m)
-38.91%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $94k | $19k | $151k | $953k | $869k | $0 | $0 | $0 | $317k | $0 | ($317k) | |
| Payments to Acquire Investments | $197.2m | $219.6m | $25.5m | $34.3m | $4.4m | $50.5m | $59.9m | $0 | $0 | — | $0 | |
| Proceeds from sales/maturities of investments | $207.4m | $183.7m | $166.1m | $99.5m | $39.1m | $0 | $68.0m | $42.5m | $0 | $0 | — | |
| Net cash (used in) provided by investing activities | $10.1m | ($35.9m) | $140.4m | $64.2m | $21.4m | ($50.5m) | $8.1m | $42.5m | ($317k) | $0 | — | |
| Net Cash Provided by (Used in) Investing Activities | $10.1m | ($35.9m) | $140.4m | $64.2m | $21.4m | ($50.5m) | $8.1m | $42.5m | ($317k) | $0 | ($189k) | |
| Cash flows from financing activities: | ||||||||||||
| Repayments of Long-term Debt | $1.6m | $1.7m | $1.0m | — | $0 | — | — | — | — | — | ($54.9m) | |
| Gain (Loss) on Extinguishment of Debt | — | — | — | $0 | $0 | $2.6m | $0 | $0 | ($54.9m) | $0 | — | |
| Non-cash loss on extinguishment of debt and exchange transaction | — | — | — | $0 | $0 | ($2.6m) | $0 | $0 | $54.9m | $0 | — | |
| Payments for Repurchase of Common Stock | — | — | — | — | $55.0m | $0 | — | — | — | — | — | |
| Proceeds from Issuance of Common Stock | — | $164.0m | — | $0 | $0 | $9.7m | $90.8m | $4.4m | $513k | $72.6m | $0 | |
| Proceeds from issuance of common stock, net of issuance costs | — | $164.0m | — | $0 | $0 | $209.0m | $0 | $52.4m | $90.7m | $72.6m | $0 | |
| Proceeds from (Payments for) Other Financing Activities | — | — | — | — | — | — | ($219k) | $21k | $29k | $244k | — | |
| Net Cash Provided by (Used in) Financing Activities | ($1.6m) |
$163.5m
+10584.80%
|
$10.7m
-93.46%
|
$136.2m
+1173.56%
|
$201.7m
+48.11%
|
$268.2m
+32.96%
|
$32.6m
-87.84%
|
$50.5m
+54.76%
|
$86.5m
+71.39%
|
$36.2m
-58.16%
|
$59.9m
+65.55%
|
|
| Net increase (decrease) in cash and cash equivalents | ($39.2m) | ($3.7m) | $2.5m | $130.1m | $137.9m | ($46.1m) | ($134.1m) | ($42.5m) | $62.5m | $23.1m | — | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | ($39.2m) | ($3.7m) | $2.5m | $130.1m | $137.9m | ($46.1m) | ($134.1m) | ($42.5m) | $62.5m | $23.1m | $156.2m | |
| Cash, cash equivalents at beginning of period | $38.2m | $34.5m | $37.0m | $167.1m | $305.0m | $258.9m | $124.8m | $82.2m | $144.8m | $167.9m | — | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | $37.0m | $167.1m | $305.0m | $258.9m | $124.8m | $82.2m | $144.8m | $167.9m | $156.2m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | $45k | $1.2m | $11.7m | $11.8m | $6.6m | $3.8m | $0 | — | — | — | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | — | — | — | — | — | $10.6m | $11.3m | $16.3m | — | |
| Income Taxes Paid, Net | — | — | — | — | — | — | — | $0 | $0 | $612k | — | |
| Additional Financial Items | ||||||||||||
| General and Administrative Expense | $18.3m | $21.4m | $33.1m | $65.9m | — | — | — | — | — | — | — | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.8m | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $59.3m | $84.6m | — | |
| Operating Costs and Expenses | — | — | — | — | — | — | — | — | — | $129.2m | — | |
| Operating Expenses | $76.2m | $169.0m | $204.6m | $241.5m | $348.9m | $305.2m | $255.0m | $271.9m | $277.9m | $342.9m | — | |
| Non-cash royalty revenue | — | — | — | — | — | — | $0 | $0 | ($26.1m) | ($55.1m) | — | |
| Non-cash interest expense related to the revenue interest liability | — | — | $0 | $8.1m | $19.6m | $33.9m | $44.6m | $46.7m | $21.6m | $0 | — | |
| Non-cash interest expense related to the royalty sale liability | — | — | — | — | — | — | $0 | $0 | $24.7m | $57.2m | — | |
| Other long-term liabilities | — | — | $0 | $0 | $1.3m | ($1.3m) | $0 | $0 | $0 | $8.7m | — | |
| Proceeds from royalty sale liability | — | — | — | — | — | — | $0 | $0 | $304.7m | $0 | — | |
| Payment of royalty sale liability issuance costs | — | — | $0 | $0 | ($8.4m) | ($440k) | $0 | $0 | ($9.6m) | $0 | — | |
| Repurchase or principal payment of revenue interest liability | — | — | — | — | — | — | ($50.0m) | $0 | ($343.8m) | $0 | — | |
| Payments on revenue interest liability | — | — | $0 | $0 | ($500k) | ($3.4m) | ($8.0m) | ($15.5m) | ($5.8m) | $0 | — | |
| Proceeds from credit agreement, net of issuance costs | — | — | — | — | — | — | $0 | $0 | $145.4m | $0 | — | |
| Proceeds from issuance of convertible notes, net of issuance costs | — | — | $0 | $0 | $280.0m | $0 | $0 | $0 | $99.7m | $0 | — | |
| Repayment of convertible notes | — | — | — | — | — | — | $0 | $0 | ($210.1m) | ($54.9m) | — | |
| Proceeds from exercise of warrants | — | — | — | — | — | — | $0 | $9.1m | $14.8m | $10.3m | — | |
| Payment of issuance costs | — | — | — | — | — | — | — | $0 | $0 | ($7.5m) | — | |
| Issuance costs not yet paid | — | — | — | $0 | $0 | $269k | $1k | $635k | $7.5m | $0 | — | |
| Non-cash right of use asset | — | — | $0 | $31k | $20k | ($7k) | $5k | $115k | $98k | $37k | — |